Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al.
作者信息
Ou S-H I, Pasi J
机构信息
Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
出版信息
Ann Oncol. 2014 Oct;25(10):2093. doi: 10.1093/annonc/mdu258. Epub 2014 Jul 17.
PMID:25035278
Abstract
摘要
Zotero 插件